What is Didroxan used for?

Didroxan is indicated for Angle-closure glaucoma, Open-angle glaucoma, Secondary glaucoma.

What development phase is Didroxan in?

Didroxan is FDA-approved (marketed).

What is the generic name of Didroxan?

DICHLOROPHEN is the generic (nonproprietary) name of Didroxan.

Last reviewed 2026-05-14 · How we verify

Didroxan (DICHLOROPHEN)

FDA-approved active Small molecule Quality 23/100

Diclorphen (Didroxan) is a marketed drug primarily indicated for angle-closure glaucoma, leveraging its mechanism of inhibiting the solute carrier family 22 member 1 to regulate intraocular pressure. Its key competitive advantage lies in its unique mechanism of action and the protection of its key composition patent, which expires in 2028. The primary risk is the presence of multiple same-target competitors, including econazole and ketoconazole, with ketoconazole being off-patent and widely available as a generic.

At a glance

Generic name	DICHLOROPHEN
Drug class	dichlorophen
Target	Solute carrier family 22 member 1
Modality	Small molecule
Therapeutic area	Ophthalmology
Phase	FDA-approved

Approved indications

Angle-closure glaucoma
Open-angle glaucoma
Secondary glaucoma

Common side effects

No common side effects on file.

Key clinical trials

Intragastric pH and Bismuth Effect for H. Pylori Eradication (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Didroxan CI brief — competitive landscape report
Didroxan updates RSS · CI watch RSS